no more tirzepatide Weight regain after the withdrawal of (Zepbound) may wipe out many of the cardiometabolic gains made during weight loss, a post-hoc analysis of the SURMOUNT-4 trial indicated. Read at: https://www.medpagetoday.com/endocrinology/obesity FDA confirms tirzepatide shortage is

Semaglutide injection has been approved by the FDA for chronic weight management in adults who are obese or overweight and have at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), in addition to a reduced-calorie diet and increased physical activity

Rapid weight loss can mobilize thyroid hormone, temporarily raising TSH

The FDA warned the public in June against taking compounded versions of the medication if the prescription forms were available

M., Roth, T., Scott, C., Birznieks, G., & Klerman, E

That receptor sits on cells in several different organs, which is why semaglutide affects hunger, blood sugar, the stomach, and the heart all at once